title: Reduction in serum clusterin is a potential therapeutic biomarker in patients with castration-resistant prostate cancer treated with custirsen.
abstract: Elevated levels of clusterin (CLU), a stress-induced and secreted cytoprotective chaperone, are associated with advanced tumor stage, metastasis, treatment resistance, and adverse outcome in several cancers. Custirsen, a second-generation antisense oligonucleotide, inhibits CLU production in tumor cells and reduces serum CLU levels. A Phase 2 study evaluated custirsen in combination with second-line chemotherapy in men with metastatic castration-resistant prostate cancer (mCRPC) who had progressed while on or within 6 months of first-line docetaxel-based chemotherapy. Exploratory analyses evaluated serum CLU levels during custirsen treatment and correlative clinical effects on prostate-specific antigen (PSA) response, overall survival, and any relationship between serum CLU and PSA. Men with mCRPC were treated with mitoxantrone/prednisone/custirsen (MPC, n = 22) or docetaxel retreatment/prednisone/custirsen (DPC plus DPC-Assigned, n = 45) in an open-label, multicenter study. Subject-specific profiles of PSA and serum CLU levels during treatment were characterized using statistical modeling to compute subject-specific summary measures; these measures were analyzed for relationship to survival using proportional hazard regression. Estimated individual serum CLU response profiles were scored as below or at/above the median level for the population through 100 days postrandomization. Median survival was longer for subjects scoring below the median serum CLU level compared with subjects at/above the median level, respectively (MPC: 15.1 months vs. 6.2 months; DPC-Pooled: 17.0 months vs. 12.1 months). Lowered serum CLU levels during custirsen treatment when in combination with either chemotherapy regimen were predictive of longer survival in mCRPC. These results support further evaluation of serum CLU as a therapeutic biomarker.
authors.affiliation: Trial Architecture Consulting Washington, District of Columbia.
authors.forename: Brent
authors.initials: B
authors.lastname: Blumenstein
authors.forename: Fred
authors.initials: F
authors.lastname: Saad
authors.forename: Sebastien
authors.initials: S
authors.lastname: Hotte
authors.forename: Kim N
authors.initials: KN
authors.lastname: Chi
authors.forename: Bernhard
authors.initials: B
authors.lastname: Eigl
authors.forename: Martin
authors.initials: M
authors.lastname: Gleave
authors.forename: Cindy
authors.initials: C
authors.lastname: Jacobs
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000097:blood / Q000235:genetics; D051152:Clusterin / Q000097:blood* / Q000235:genetics*; D006801:Humans; D008297:Male; D016376:Oligonucleotides, Antisense / Q000008:administration & dosage*; D009919:Orchiectomy; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood* / Q000401:mortality / Q000601:surgery / Q000628:therapy*; D013873:Thionucleotides / Q000008:administration & dosage*; D016896:Treatment Outcome
chemical_list: D014408:Biomarkers, Tumor; D051152:Clusterin; C503781:OGX-011; D016376:Oligonucleotides, Antisense; D013873:Thionucleotides; D017430:Prostate-Specific Antigen
keywords: Antisense oligonucleotide; chemotherapy; clusterin; custirsen; mCRPC